Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL2679835

C[n+]1ccn(CC(F)(F)F)c1.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 1/20 0.36
APAF1 O14727 1/20 0.36
NPC1 O15118 1/20 0.36
PLA2G1B P04054 1/20 0.36
HSP90AA1 P07900 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
KCNH2 Q12809 7/20 0.33
ACHE P22303 6/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425219 0.86 FDPS (0.47) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL133213 0.85 FDPS (0.40) FDPSSMN1; SMN2MEN1APAF1NPC1
SCHEMBL2934584 0.84 FDPS (0.40) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL319658 0.83 SMN1; SMN2 (0.49) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL2914064 0.81 SMN1; SMN2 (0.41) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL27174984 0.81 FDPS (0.44) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL29390371 0.80 MEN1 (0.58) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL4920095 0.80 FDPS (0.37) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL294105 0.80 MEN1 (0.58) FDPSSMN1; SMN2MEN1APAF1NPC1
Trifluoromethanesulfonic Acid SCHEMBL4553127 0.80 FDPS (0.40) FDPSSMN1; SMN2MEN1APAF1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252944-B2 Process for preparing heteroaromatic ring compound having N-Rf group DAIKIN INDUSTRIES, LTD. (JP) 2012-08-28 US disclosed
US-8212053-B2 Process for preparing heteroaromatic ring compound having N-Rf group DAIKIN INDUSTRIES, LTD. (JP) 2012-07-03 US disclosed
US-20120116097-A1 PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP DAIKIN INDUSTRIES, LTD. (JP) 2012-05-10 US disclosed
US-20100222598-A1 PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP DAIKIN INDUSTRIES, LTD. (JP) 2010-09-02 US disclosed
EP-1975157-A1 METHOD FOR PRODUCTION OF HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP Daikin Industries, Ltd. (JP) 2008-10-01 EP disclosed
US-20050175867-A1 Mixture of two or more organic salts; reduced melting point; low temperature stability; polymer electrolyte fuel cells, dye sensitized solar cells, biological batteries DAIKIN INDUSTRIES, LTD (JP) 2005-08-11 US disclosed
JP-2003062467-A ION LIQUID COMPOSITION CENTRAL GLASS CO LTD 2003-03-04 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222598-A1 PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP CYP2F1, AFF1, AFF2 FDPS 93/4885SMN1; SMN2 4432/4885MEN1 2236/4885
US-20050175867-A1 Mixture of two or more organic salts; reduced melting point; low temperature stability; polymer electrolyte fuel cells, dye sensitized solar cells, biological batteries CA2, CA12, CA4 FDPS 1529/4885SMN1; SMN2 1660/4885MEN1 149/4885
US-20120116097-A1 PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP CYP2F1, AFF1, AFF2 FDPS 93/4885SMN1; SMN2 4432/4885MEN1 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.